Press Release
Bharuch (Gujarat), India, April 11, 2012

Jubilant SEZ facility at Bharuch, Gujarat to be inaugurated by Shri Narendra Modi, Hon'ble Chief Minister of Gujarat on April 13, 2012

Jubilant Life Sciences Ltd, an integrated Pharmaceutical and Life Sciences Company and the largest Custom Research & Manufacturing player from India announced today that its new state-of-the-art Special Economic Zone (SEZ) spread over 300 acre in Vilayat Industrial Estate, District Bharuch, Gujarat will be inaugurated by Shri Narendra Modi, Hon'ble Chief Minister of Gujarat on Friday, April 13, 2012.

Jubilant Infrastructure Ltd., a wholly owned subsidiary of Jubilant Life Sciences Ltd. entered into a Memorandum of Understanding (MOU) with the Government of Gujarat during the "Vibrant Gujarat" Conference in 2007 for development of an SEZ at GIDC Industrial Estate, Vilayat, District Bharuch. In pursuance of this MOU, in 2009, the Company had initiated work to build a world class SEZ for Chemical Industry.

Commenting on the development, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, said, "We are setting up global size world class manufacturing facilities in Gujarat to fulfil our vision of leadership position in chosen areas of business. Gujarat being the natural choice to set up this facility, we are thankful to the State Government under the leadership of the Hon'ble Chief Minister, for their constant encouragement, guidance and support."

The finished products from this facility would be fully backward integrated and based on in-house developed innovative technologies, making it a hub for world class quality products offering value to all stakeholders.

The global scale plants of Vitamin B3 and 3-Cyanopyridine, at SEZ make Jubilant the largest producer of Vitamin B3 in India and second largest globally. The Company is also setting up a manufacturing plant at SEZ for Symtet, a crop science ingredient for one of the world's largest and safest low cost insecticide through an environment friendly process. This will make Jubilant the world's largest producer of the crop science ingredient for the insecticide through green route.

About Jubilant Life Sciences
Jubilant Life Sciences Limited is an integrated Pharmaceuticals and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution provider out of India. The Company provides Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities and a team of 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 75 countries. The Company is well recognized as a 'Partner of Choice' by leading life sciences companies worldwide. For more info: www.jubl.com

For more information please contact:

For Media
Sudhakar Safaya
Jubilant Life Sciences Limited
+91 - 0120 4361034; +91 - 9811219334
Email - sudhakar_safaya@jubl.com

For Investors
Nidhi Aggarwal
Jubilant Life Sciences Limited
Ph: +91-120 4361002
E-mail: nidhi_aggarwal@jubl.com

Siddharth Rangnekar
Citigate Dewe Rogerson
Tel: +91 -22 6645 1209
E-mail: siddharth@cdr-india.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

distributed by